<DOC>
	<DOCNO>NCT00755404</DOCNO>
	<brief_summary>The current study initiate order ass impact PD solution contain L-carnitine insulin sensitivity evaluate measure insulin requirement .</brief_summary>
	<brief_title>Effect L-Carnitine-Containing Peritoneal Dialysis ( PD ) Solution Insulin Sensitivity Diabetic Patients Continuous Ambulatory Peritoneal Dialysis ( CAPD )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Age ≥18 year 2 . Have diagnosis ESRD Continuous Ambulatory Peritoneal Dialysis ( CAPD ) least 3 month 3 . Have Type 2 Diabetes , diagnose accord American Diabetes Association ( fast glucose ≥126 mg/dl 2 h glucose OGTT ≥200 mg/dl ) , treat multiple daily insulin injection HbA1c &gt; 8.5 % ( No oral antidiabetic ) 4 . Be stable clinical condition four week immediately prior Screening Period demonstrate medical history , physical examination laboratory test 5 . Have blood hemoglobin concentration 8,5 g/100ml ( data verify Investigators ) 6 . Have experience peritonitis episode last 3 month 7 . Be treat Extraneal ( nocturnal exchange bag solution ) least 1 month 8 . Be treat 3 diurnal exchange bag solution ( solution bags 1.5 % 2.5 % glucose ) one nocturnal exchange bag solution ( Extraneal ) 9 . Have Kt/V urea measurement &gt; 1.7 per week previous test perform within 3 month confirm Baseline Visit 10 . Have minimum weekly creatinine clearance 45 litres previous test perform within 6 month confirm Baseline Visit 11 . Have D/P Creatinine ratio Peritoneal Equilibration Test ( PET ) 0.50 0.81 previous test perform within 6 month confirm Baseline Visit 12 . Have D/P Glucose ratio Peritoneal Equilibration Test ( PET ) 0.26 0.49 previous test perform within 6 month confirm Baseline Visit 13 . Be treat participate clinical Investigator period least three month 14 . Have understood sign Informed Consent Form . 1 . Have history drug alcohol abuse six month prior enter protocol 2 . Type 2 Diabetic patient oral antidiabetic treatment HbA1C &lt; 8.5 % 3 . Be treatment androgens 4 . Have clinically significant abnormal liver function test ( SGOT , SGPT , gammaGT &gt; 2 time upper normal limit ) 5 . Have acute infectious condition ( i.e . : pulmonary infection , acute hepatitis , high low urinary tract infection , renal parenchymal infection , pericarditis , etc ) 6 . Have history congestive heart failure clinically significant arrhythmia 7 . Have history epilepsy CNS disease 8 . Have malignancy within past 5 year , include lymphoproliferative disorder 9 . Have medical condition , judgment Investigator , would jeopardize patient 's safety follow exposure study drug 10 . Have history LCarnitine therapy use month prior enter protocol 11 . Have use investigational drug 3 month prior enter protocol 12 . Be pregnancy , lactation , fertility age without protection pregnancy adequate contraceptive mean</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Peritoneal dialysis</keyword>
	<keyword>L-carnitine</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Glucose homeostasis</keyword>
	<keyword>Dyslipidemia</keyword>
</DOC>